Published in Gene Therapy Weekly, December 8th, 2005
"Protein transduction therapy using poly-Arg can deliver the bioactive p53 protein into cancer cells and inhibits the proliferation of the cells. However, one disadvantage of such therapy is the short intracellular half-life of the delivered protein."
"The mutant proteins were effectively delivered...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly